The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questions regarding this study, please contact Kate Cernok, PhD at kcernok@santeninc.com.
SAKURA Phase III Study
The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment. DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory agent. If you have been diagnosed with uveitis of the posterior segment or if you have questionsLearn More
November 13, 2015
Categories
Recent Posts
- Blog: My Journey with Neurosarcoidosis
- Sarcoidosis Test Aims to Speed, Simplify Diagnostic Process
- FSR Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
- FSR and Walgreens Unite in Alabama to Boost Sarcoidosis Awareness and Spring Vaccine Education
- FSR Launches Say Sarcoidosis Campaign for April’s Awareness Month